CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Metabolix,
Inc. (NASDAQ: MBLX), a bioscience company focused on developing
clean, sustainable solutions for plastics, chemicals and energy, today
announced that it has appointed Celeste Beeks Mastin to its board of
directors. Ms. Mastin brings more than 20 years of experience in the
global chemicals and performance materials sector to the Company's
board. The appointment is effective as of Thursday, January 19, 2012.
Richard P. Eno, president and CEO of Metabolix, commented, "Celeste
has an impressive track record of accomplishment in the global chemicals
and performance materials sector. We expect to benefit from her deep
operating experience in sales and marketing and proven leadership
ability as we develop and implement effective strategies to
commercialize our leading-edge technology in both PHA bioplastics and
renewable industrial chemicals."
Ms. Mastin recently served as chief executive officer of MMI Products,
Inc., where she had profit/loss responsibility for a $750 million
building materials company with 18 manufacturing locations and 2,500
employees. Prior to MMI Products, she spent 17 years in the chemical
industry. At Ferro Corporation, she held the role of vice president of
Color and Glass Performance Materials, with profit/loss responsibility
for a $400 million global business, and the role of vice president of
growth and development. Ms. Mastin started her career in sales at Shell
Chemical, where she served five years in sales positions of increasing
responsibility. Her sales experience expanded at Bostik, Inc., where she
held European and later global sales management positions, with her
career at Bostik culminating in the role of vice president/general
manager of Nonwovens, a $200 million global adhesives business. Ms.
Mastin holds a bachelor's degree in chemical engineering from Washington
State University and a master's degree in business administration from
the University of Houston.
Ms. Mastin commented, "The increasing demand for bioplastics and
renewable chemicals to meet the sustainable needs of businesses and
consumers makes this a market poised for growth. Metabolix's unique,
proprietary technology platforms are among the most advanced in the
industry and I am looking forward to joining the company's board of
directors and helping to position Metabolix for commercial success."
About Metabolix
Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience
company focused on providing sustainable solutions for the world's needs
for plastics, chemicals and energy. The Company is taking a systems
approach, from gene to end product, integrating sophisticated
biotechnology with advanced industrial practice. Metabolix is developing
biosourced industrial chemicals and plastics, as well as a proprietary
platform technology for co-producing plastics, chemicals and energy,
from crops such as switchgrass, oilseeds and sugarcane.
For more information, please visit www.metabolix.com.
(MBLX-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The forward-looking statements in this release do
not constitute guarantees of future performance. Investors are cautioned
that statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding
expectations for commercialization of Metabolix technology and market
demand for bioplastics and renewable chemicals, constitute
forward-looking statements. Such forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated and are detailed in
Metabolix's filings with the Securities and Exchange Commission.
Metabolix assumes no obligation to update any forward-looking
information contained in this press release or with respect to the
announcements described herein.
Media:
Metabolix
Lynne Brum, 617-682-4693
LBrum@metabolix.com
or
Schwartz
msl
Keith Giannini or Jen Barlow, 781-684-0770
metabolix@schwartzMSL.com
or
Investors:
ICR
James
Palczynski, 203-682-8229
james.palczynski@icrinc.com
Source: Metabolix, Inc.
News Provided by Acquire Media